Nabriva Therapeutics (NASDAQ:NBRV) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

A number of other research firms have also weighed in on NBRV. Zacks Investment Research lowered Nabriva Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 19th. Needham & Company LLC restated a “buy” rating and issued a $18.00 target price on shares of Nabriva Therapeutics in a report on Wednesday, July 25th. Bank of America set a $5.00 target price on Nabriva Therapeutics and gave the company a “buy” rating in a report on Monday, August 27th. Finally, Morgan Stanley assumed coverage on Nabriva Therapeutics in a report on Friday, September 7th. They issued an “overweight” rating and a $8.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. Nabriva Therapeutics presently has a consensus rating of “Buy” and an average price target of $11.67.

Shares of NASDAQ:NBRV opened at $2.09 on Wednesday. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of -0.84 and a beta of 1.47. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.52 and a current ratio of 7.52. Nabriva Therapeutics has a 52-week low of $2.09 and a 52-week high of $6.94.

Nabriva Therapeutics (NASDAQ:NBRV) last posted its earnings results on Thursday, August 9th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.04. Nabriva Therapeutics had a negative return on equity of 77.40% and a negative net margin of 642.38%. The company had revenue of $0.85 million for the quarter, compared to analyst estimates of $1.16 million. Equities research analysts anticipate that Nabriva Therapeutics will post -1.54 earnings per share for the current year.

In related news, Director Daniel D. Burgess bought 36,000 shares of the company’s stock in a transaction dated Tuesday, July 31st. The shares were bought at an average price of $2.75 per share, for a total transaction of $99,000.00. Following the completion of the acquisition, the director now directly owns 36,000 shares of the company’s stock, valued at $99,000. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.15% of the stock is owned by company insiders.

Institutional investors have recently modified their holdings of the stock. Wedbush Securities Inc. bought a new stake in Nabriva Therapeutics during the second quarter worth $371,000. Prosight Management LP lifted its holdings in Nabriva Therapeutics by 73.6% during the second quarter. Prosight Management LP now owns 421,414 shares of the biotechnology company’s stock worth $1,467,000 after acquiring an additional 178,725 shares during the period. BlackRock Inc. lifted its holdings in Nabriva Therapeutics by 154.0% during the first quarter. BlackRock Inc. now owns 453,064 shares of the biotechnology company’s stock worth $2,278,000 after acquiring an additional 274,709 shares during the period. JPMorgan Chase & Co. lifted its holdings in Nabriva Therapeutics by 163.9% during the first quarter. JPMorgan Chase & Co. now owns 24,959 shares of the biotechnology company’s stock worth $126,000 after acquiring an additional 15,501 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in Nabriva Therapeutics by 173.2% during the first quarter. Dimensional Fund Advisors LP now owns 111,865 shares of the biotechnology company’s stock worth $563,000 after acquiring an additional 70,917 shares during the period. Institutional investors and hedge funds own 3.17% of the company’s stock.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

See Also: What is the balance sheet?

Analyst Recommendations for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.